Abnormal liver function tests occur in 3-5% of pregnancies, with many potential causes, including coincidental liver disease (most commonly viral hepatitis or gallstones) and underlying chronic liver disease. Pruritus in pregnancy is common, affecting 23% of pregnancies, of which a small proportion will have obstetric cholestasis. Intrahepatic cholestasis of pregnancy (ICP) is a cholestatic disorder characterized by pruritus with onset in the second or third trimester of pregnancy, elevated serum aminotransferases and bile acid levels, and spontaneous relief of signs and symptoms within two to three weeks after delivery. ICP is observed in 0.4-1% of pregnancies in most areas of Central and Western Europe and North America. Genetic and hormonal factors, but also environmental factors may contribute to the pathogenesis of ICP. Intrahepatic cholestasis of pregnancy increases the risk of preterm delivery (19- 60%), meconium staining of amniotic fluid (27%), fetal bradycardia (14%), fetal distress (22-41%), and fetal loss (0.4-4.1%), particularly when associated with fasting serum bile acid levels >40 μmol/L. Important ICP-induced changes in serum profiles of amidated bile acids were observed, involving both a marked increase in cholic acid concentration and a shift towards a higher proportion of taurine-conjugated species. Ursodeoxycholic acid (10-20 mg/kg/d) is today regarded as the first line treatment for intrahepatic cholestasis of pregnancy. Delivery has been recommended in the 37-38th week when lung maturity has been established.
Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet Journal of Rare Diseases. 2007;26.
2.
Ahlfeld. Grunow FW.
3.
Abu-Hayyeh S, Papacleovoulou G, Lovgren-Sandblom A, Tahir M, Oduwole O, Jamaludin N, et al. Intrahepatic Cholestasis of Pregnancy Levels of Sulfated Progesterone Metabolites Inhibit Farnesoid X Receptor Resulting in a Cholestatic Phenotype. HEPATOLOGY. 2013;716–26.
4.
Turunen K, Molsa A, Helander K, Sumanen M, Mattila K. Health history after intrahepatic cholestasis of pregnancy. Nordic Federation of Societies of Obstetrics and Ginecology. 2012;679–85.
5.
Reyes H, Ba´ez M, Gonza´lez M, Herna´ndez I, Palma J, Ribalta J. Selenium, zinc and copper plasma levels in intrahepatic cholestasis of pregnancy, in normal pregnancies and in healthy individuals. J Hepatol. 2000;542–9.
6.
Hay J. Liver Disease in Pregnancy. HEPATOLOGY. 2008;1067–76.
7.
Van Der Woerd W, Van Mil S, Stapelbroek J, Klomp L, Van De Graaf S, Houwen R. Familial cholestasis: Progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Practice & Research Clinical Gastroenterology. 2010;541–53.
8.
Van Mil S, Houwen R, Klomp L. Genetics of familial intrahepatic cholestasis syndromes. J Med Genet. 2005;449–63.
9.
Van Mil S, Klomp L, Bull L, Houwen R. FIC1 disease: a spectrum of intrahepatic cholestatic disorders. Semin Liver Dis. 2001;535–44.
10.
Bull L, Carlton V, Stricker N, Baharloo S, Deyoung J, Freimer N. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. Hepatology. 1997;155–64.
11.
Klomp L, Vargas J, Van Mil S, Pawlikowska L, Strautnieks S, Van Eijk M. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology. 2004;27–38.
12.
Strautnieks S, Byrne J, Pawlikowska L, Cebecauerová D, Rayner A, Dutton L. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008;1203–14.
13.
Elferink O, Paulusma R, C. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch. 2007;601–10.
14.
Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E. Liver diseases related to MDR3 (ABCB4) gene deficiency. Front Biosci. 2009;4242–56.
15.
Sundaram S, Sokol R. The multiple facets of ABCB4 (MDR3) deficiency. Curr Treat Options Gastroenterol. 2007;(6):495–503.
16.
Vallejo M, Briz O, Serrano M, Monte M, Marin J. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol. 2006;1150–7.
17.
Abu-Hayyeh S, Martinez-Becerra P, Abdul Kadir S, Selden S, Romero C, Rees M, et al. Inhibition of Na+-taurocholate cotransporting polypeptide mediated bile acid transport by cholestatic sulphated progesterone metabolites. J Biol Chem. 2010;16504–12.
18.
Mays J. The active management of intrahepatic cholestasis of pregnancy. Curr Opin Obstet Gynecol. 2010;100–3.
19.
Lucena J, Herrero J, Quiroga J, Sangro J, Garcia-Foncillas B, Zabalegui J, et al. A Multidrug Resistance 3 Gene Mutation Causing Cholelithiasis, Cholestasis of Pregnancy, and Adulthood Biliary Cirrhosis GASTROEN. TEROLOGY. 2003;1037–42.
20.
Savander M, Ropponen A, Avela K, Weerasekera N, Cormand B, Hirvioja M. Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut. 2003;1025–9.
21.
Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomaki K. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology. 2006;723–8.
22.
Shobaili A, H, Ho H, Robaee A, Alzolibani A, Amin A, et al. Obstetrical and fetal outcomes of a new management strategy in patients with intra-hepatic cholestasis of pregnancy. Arch Gynecol Obstet. 2011;1219–25.
23.
Glantz A, Marschall H, Mattsson L. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology. 2004;467–74.
24.
Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol. 2009;2049–66.
25.
Sepu´lveda W, Gonza´lez C, Cruz M, Rudolph M. Vasoconstrictive effect of bile acids on isolated human placental chorionic veins. Eur J Obstet Gynecol Reprod Biol. 1991;211–5.
26.
Reid R, Ivey K, Rencoret R, Storey B. Fetal complications of obstetric cholestasis. Br Med J. 1976;870–2.
27.
Brites D. Intrahepatic cholestasis of pregnancy:Changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. Annals of hepatology. 2002;(1):20–8.
28.
Pasanen M, Helin-Martikainen H, Pelkonen O, Kirkinen P. Intrahepatic cholestasis of pregnancy impairs the activities of human placental xenobiotic and steroid metabolizing enzymes in vitro. Placenta. 1997;37–41.
29.
Castano G, Lucangioli S, Sookoian S, Mesquida M, Lemberg A, Scala D, et al. Bile acid profiles by capillary electrophoresis in intrahepatic cholestasis of pregnancy. Clin Sci (Lond). 2006;459–65.
30.
Brites D, Rodrigues C, Van-Zeller H, Brito A, Silva R. Relevance of serum bile acid profile in the diagnosis of intrahepatic cholestasis of pregnancy in an high incidence area: Portugal. Eur J Obstet Gynecol Reprod Biol. 1998;31–8.
31.
Laatikainen T, Lehtonen P, Hesso A. Biliary bile acids in uncomplicated pregnancy and in cholestasis of pregnancy. Clin Chim Acta. 1978;145–50.
32.
Bacq Y, Myara A, Brechot M, Hamon C, Studer E, Trivin F, et al. Serum conjugated bile acid profile during intrahepatic cholestasis of pregnancy. J Hepatol. 1995;66–70.
33.
Williamson C, Gorelik J, Eaton B, Lab M, De Swiet M, Korchev Y. The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis. Clin Sci. 2001;363–9.
34.
Saleh M, Abdo K. Consensus on the management of obstetric cholestasis: National UK survey. BJOG. 2007;99–103.
35.
Johnston W, Baskett T. Obstetric cholestasis. A 14 year review. Am J Obstet Gynecol. 1979;299–301.
36.
Oztekin D, Aydal I, Oztekin O, Okcu S, Borekci R, Tinar S. Predicting fetal asphyxia in intrahepatic cholestasis of pregnancy. Arch Gynecol Obstet. 2009;975–9.
37.
Zecca E, Luca D, Barbato D, Marras G, Tiberi M, Romagnoli E, et al. Predicting respiratory distress syndrome in neonates from mothers with intrahepatic cholestasis of pregnancy. Early Hum Dev. 2008;337–41.
38.
Mullally B, Hansen W. Intrahepatic cholestasis of pregnancy: review of the literature. Obstet Gynecol Surv. 2002;47–52.
39.
Reid R, Ivey K, Rencoret R, Storey B. Fetal complications of obstetric cholestasis. Br Med J. 1976;870–2.
40.
Germain A, Kato S, Carvajal J, Valenzuela G, Valdes G, Glasinovic J. Bile acids increase response and expression of human myometrial oxytocin receptor. Am J Obstet Gynecol. 2003;577–82.
41.
Israel E, Guzman M, Campos G. Maximal response to oxytocin of the isolated myometrium from pregnant patients with intrahepatic cholestasis. Acta Obstet Gynecol Scand. 1986;581–2.
42.
Campos G, Guerra F, Israel E. Effects of cholic acid infusion in fetal lambs. Acta Obstet Gynecol Scand. 1986;23–6.
43.
Falconer J, Smith A, Eastwood M. The effects of bile acids on colonic motility in the rabbit. Q J Exp Physiol Cogn Med Sci. 1980;135–44.
44.
Serrano M, Brites D, Larena M, Monte M, Bravo M, Oliveira N, et al. Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta. J Hepatol. 1998;829–39.
45.
Glantz A, Marschall H, Lammert F, Mattsson L. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology. 2005;1399–405.
46.
Zapata R, Sandoval L, Palma J, Hernandez I, Ribalta J, Reyes H, et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience. Liver Int. 2005;548–54.
47.
Poupon R. Intrahepatic cholestasis of pregnancy: from bedside to bench to bedside. Liver Int. 2005;467–8.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
